

## CURRICULUM VITAE

**Brage Storstein Andresen** - Born 7. February 1965 in Oslo, Norway. Married – Three children.

Work address: Dept. of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense S, Denmark.

### Academic degrees

- 1991** M.Sc. (Molecular Biology), Aarhus University (AU), Denmark.  
**1996** Ph.D. (Medicine) Faculty of Health, AU.  
**2015** FRCPath. (Molecular Genetics) (Fellow of The Royal College of Pathologists, UK).

### Positions

- 1995-1997** Assistant professor, Molecular Genetic Laboratory, Aarhus University hospital -Skejby Sygehus and Dept. of Experimental Clinical Research, AU.  
**1997-2008** Associate professor, Dept. Human Genetics, AU.  
**2004** Visiting professor, Dept. Pediatrics, Vanderbilt Univ. Medical School, TN, USA.  
**2008** Visiting Scientist, Cold Spring Harbor Laboratory, NY, USA.  
**2008 -2014** Professor (WSR) of Eukaryotic Gene Regulation and Metabolism, Dept. of Biochem. & Mol. Biol., University of Southern Denmark (SDU).  
**2014 -** Professor of Human Molecular Genetics, Dept. of Biochem. & Mol. Biol., SDU.  
**2018 -2021** Deputy Head of Department, Dept. of Biochem. & Mol. Biol. (BMB), SDU.  
**2018 -** Head of Section for Translational Biology, Dept. of Biochem. & Mol. Biol., SDU.  
**2024-** Founder and CSO of Inverna Therapeutics Aps.

### Fellowships

- 1993-1995** Fellowship. Danish Medical Research Council (now FSS).  
**1995-1997** Senior fellowship. Danish Medical Research Council (now FSS).

### Other education

- 1996** Pedagogical Training course, Sandbjerg gods, AU.  
**2009** Research Management Course, Copenhagen School of Business.  
**2011** SDU's Leadership Development Program.

**Academic work 155 peer-reviewed articles + 17 book chapters/Invited articles.**

**SCOPUS: H-index = 47 6825 citations. Google Scholar: H-Index = 53 >9248 citations I10=136**

**ORCID: 0000-0001-7488-3035**

Full list of publications:

<https://www.ncbi.nlm.nih.gov/pubmed/?term=andresen+bs+not+fomsgaard>

Presented **>50 oral presentations** international meetings.

### Patents:

1. "RAS Exon 2 skipping for cancer treatment" - PCT/EP2014/078029 Published: WO 2015/091525.
2. "Splice switching oligonucleotides targeting pseudoexons" - Request for European Patent: 75540EP01 26/1-21. (PCT/EP2022/051790). WO2022/162020A2 published 0408-2022. EPO:
3. "Splice shifting oligonucleotides for use in the treatment of diseases characterized by altered inclusion of microexons" - PCT/EP2022/077882 EPO:WO/2023/057575.
4. "Allele specific splice switching oligonucleotides targeting pseudoexons" - PA 2022-70346 (75550DK01). Published WO2023/144263

**Evaluator** EU Horizon 2020-PHC14; EU Horizon 2020-SC1-PM-08-2017; EU Horizon 2020-FETFLAG-01- and 02-2018; EU Innovative Medicines Initiative's Research & Innovation Action (IMI2) 2020 and EU ERC (2015); Swedish-, Canadian-, Dutch-, Japanese-, Irish- (2016-2023), Romanian- Faroese- Estonian- Israeli-, and Swiss- National Research Councils; Prinses Beatrix Fonds (NL) and Institut National du Cancer (InCa - France) (2017-2024).

**Editorial Boards** *Molecular Genetics and Metabolism*, Elsevier (2007-); *Human Mutation*, Wiley (2021-)

### Committees

Scientific Advisory Group, UK Collab. Study Newborn Screening MCADD (2004-11)  
Workgroup for evaluation of Newborn Screening in DK. Danish National Board of Health (2005-09)  
Steering group Newborn Screening in Denmark (2003-)  
Chair of teaching, Dept. Hum Genet., AU (2007-08) and BMB, SDU (2015-21), Educational board, BMB, SDU (2009-21), Study board, Faculty of Science, SDU (2018-2020)  
Department Council, BMB, SDU (2013-2020)  
Steering group for Villum Center for Bioanalytical Sciences (2013-19)  
Faculty member "Graduate Program for Real World Data Informatics–JUN-KAN" supported by JSPS <http://www.jsps.go.jp/english/e-hakasekatei/index.html>, Nagoya Univ. Med. School, Japan, 2013-20.  
Executive board: Nordic Network Biomedicine/Nordplus/ERASMUS+, OERCompBiomed (2017-21),  
Executive board: Danish RNA Society (2022-), Scientific Advisory Board: EFFeCT - MSCA Doctoral Network (2024-),  
Partner in DECODES consortium MSCA Doctoral Network (application 2025-) Chair of the Danish RNA Society (2025-)

### Current supervision

5 Postdocs and 3 MSc-students.

### Management experience

Head of Research lab with 15-20 people

Deputy Head of Dept., BMB, SDU (2018-21) (Responsible for 3 educations/Secretariat: 3 employees)

Member of Department management group, BMB, SDU (2018-)

Chair of teaching, Dept. Hum Gen, AU (2007-08) and BMB, SDU (2015-21)

Head of Section for Translational Biology, SDU (5 Labs – 60 people) (2018-)

Founder, CSO and Board member of Inverna Therapeutics Aps.

### Current main international collaborators

Prof. Lourdes Ruiz Desviat, Universidad Autonoma Madrid, Spain.

Prof. Jose Lucas, Universidad Autonoma Madrid, Spain.

Prof. Michelle Hastings, Director, Center for RNA Biomedicine, University of Michigan, USA.

Prof. and Vice Dean, Kinji Ohno, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Prof. Juan Valcarcel, Centre for Genomic Regulation (CRG), Barcelona, Spain.

Prof. Michael Sattler, Helmholtz Zentrum München, Technische Universität München, Germany.

### Recent major research funding

**Danish Medical Research Council (FSS)** 2015-19 and 2019-22; **Danish Research Council for Natural Science (FNU)** 2015-19, 2020-2023, 2023-2026; **Novo Nordisk Foundation:** 2024-26, 2022-23; 2020-22, 2018-20; **NNF Pioneer grant:** 2025-26, **Innoexplorer:** 2023-24; **ArgoBio Studio (France):** 2023-; **SDU POC:** 2024-2026. **Michael J Fox Foundation (US):** 2025-2027.

**Societies** *The American Society of Human Genetics; European Society of Human Genetics; Society for the Study of Inborn Errors of Metabolism, RNA Society, Danish RNA Society (Board member), Danish Society for Medical Genetics, Oligonucleotide Therapeutics Society, American Society of Gene & Cell Therapy.*

### PUBLICATION LIST

**Total 172 articles - Peer review: 155 - Not-peer review: 17**

**Patents: 4 published – 1 granted**

**SCOPUS: H-index = 47 6825 citations.**

**Google Scholar: H-Index = 53 >9248 citations I10=136**

**ORCID: 0000-0001-7488-3035**

**Scopus Author ID: 35866781200**

Full list of publications:

<https://www.ncbi.nlm.nih.gov/pubmed/?term=andresen+bs+not+fomsgaard>

1. Møller BK, **Andresen BS**, Christensen EI, Petersen CM (1990) Surface membrane CD4 turnover in PMA stimulated T-Lymphocytes: evidence of degradation and increased synthesis. *FEBS letters* 276:59-62.
2. Gregersen N, **Andresen BS**, Bross P, Winter V, Rudiger N, Engst S, Christensen E, Kelly D, Strauss A, Kølvråa S, Bolund L and Ghisla S (1991) Molecular characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: Identification of a lys<sup>329</sup> to glu mutation in the MCAD gene, and expression of inactive mutant protein in *E. coli*. *Human Genetics* 86:545-551.
3. Gregersen N, **Andresen BS**, Bross P, Winter V, Engst S, Blakemore A, Curtis D, Engel P, Kelly D, Strauss AW, Kølvråa S, Bolund L and Ghisla S (1991) Characterization of a disease-causing Lys329 to Glu mutation in 16 patients with medium-chain acyl-CoA dehydrogenase deficiency. *J Inher Metab Dis.* 14:314-316.
4. Kølvråa S, Gregersen N, Blakemore A, Schneidermann A, Winter V, **Andresen BS**, Curtis D, Engel P, Divry P, Rhead W and Bolund L (1991) The most common mutation causing medium-chain acyl-CoA dehydrogenase (MCAD) deficiency probably occurs exclusively on chromosomes with a particular haplotype in the region of the gene. *Human Genetics* 87:425-429.
5. Gregersen N, Blakemore A, Winter V, **Andresen BS**, Kølvråa S, Bolund L, Curtis D and Engel P (1991) Specific diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in dried blood spots by a Polymerase Chain Reaction (PCR) assay detecting a point-mutation (G985) in the MCAD gene. *Clin -Chim Acta* 203:23-34.
6. Gregersen N, Winter V, **Andresen BS**, Kølvråa S, Christensen E, Petersen BN og Bolund L (1992) Mellem-kædet acyl-CoA dehydrogenase (MCAD) mangel: En livstruende fedtsyreoxidaationsdefekt. *Ugesk Læger* 156:483-488.
7. Petersen CM, Christensen EI, **Andresen BS**, Møller BK (1992) Internalization, Lysosomal degradation and new-synthesis of surface membrane CD4 in phorbol ester activated T-lymphocytes and U-937 cells. *Exp Cell Res* 201:160-173.
8. **Andresen BS**, Knudsen I, Jensen PKA, Rasmussen K and Gregersen N (1992) Two novel non-radioactive PCR-based assays in which dried blood -spots, genomic DNA or whole cells are used for fast and reliable detection of the Z and S mutations in the gene for a-1-anti-trypsin. *Clinical Chemistry* 38:2100-2107.
9. Jensen TG, **Andresen BS**, Bross P, Jensen UB, Holme E, Kølvråa S, Gregersen N and Bolund L (1992) Expression of wildtype and mutant medium-chain acyl-CoA dehydrogenase (MCAD) cDNA in eucaryotic cells. *Biochim Biophys Acta* 1180:65-72.
10. **Andresen BS**, Bross P, Jensen TG, Winter V, Kølvråa S, Jensen UB, Bolund L, Curtis D, Duran M, Kim JJP, Vianey-Saban C, Divry P and Gregersen N (1993) A rare disease-associated mutation in the gene for Medium Chain Acyl-CoA

- dehydrogenase (MCAD) changes a conserved arginine residue previously shown to be functionally essential in Short-Chain Acyl-CoA dehydrogenase (SCAD). *Am J Hum Genet* 53:730-739.
11. **Andresen BS**, Kølvrå S, Bross P, Bolund L, Curtis D, Eiberg H, Zhang ZF, Kelly DP, Strauss AW and Gregersen N (1993) A silent A to G mutation in exon 11 of the Medium Chain Acyl-CoA dehydrogenase (MCAD) gene. *Hum Mol Genet* 2:488.
  12. Gregersen N, Winter V, Curtis D, Deufel T, Mack M, Willems PJ, Ponzzone A, P-a-r-r-el-la T, Ponzzone R, Ding JH, Zhang W, Chen YT, Kahler S, Roe CR, Kølvrå S, Schneiderman K, **Andresen BS**, Bross P and Bolund L (1993). Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency: The prevalent mutation G985 (K304E) is subject to a strong founder effect from North-western Europe. *Human Heredity* 43:342-350.
  13. Tanaka K, Yokota I, Coates PM, Strauss AW, Kelly DP, Zhang Z, Gregersen N, **Andresen BS**, Matsubara Y, Curtis D and Chen YT (1992) Mutations in the Medium-Chain Acyl-CoA Dehydrogenase (MCAD) gene. *Hum Mutat* 1:271-279.
  14. Bross P, **Andresen BS**, Winter V, Krautle F, Jensen TG, Kølvrå S, Rasched I, Ghisla S, Bolund L and Gregersen N (1993) Coexpression of bacterial Gro-ESL chaperonins partly overcomes unproductive folding and tetramer assembly in E. coli expressing human medium-chain acyl-CoA dehydrogenase (MCAD) carrying a prevalent point mutation A985G found in patients with MCAD deficiency. *Biochim Biophys Acta* 1182:264-274.
  15. **Andresen BS**, Jensen TG, Bross P, Knudsen I, Winter V, Kølvrå S, Bolund L, Ding JH, Chen YT, VanHove JLK, Curtis D, Yokota I, Tanaka K, Kim JJP and Gregersen N (1994) Disease-causing mutations in exon 11 of the Medium Chain Acyl-CoA dehydrogenase (MCAD) gene. *Am J Hum Genet* 54:975-988.
  16. Gregersen N, Winter V, Lyonnet S, Saudubray JM, Wendel U, **Andresen BS**, Kølvrå S, Bolund L and Bross P (1994) Molecular characterization and urinary excretion pattern of metabolites in two families with MCAD deficiency due to compound heterozygosity with a 13 basepair insertion in one allele. *J Inher Metab Dis* 17:169-184.
  17. **Andresen BS**, Bross P, Knudsen I, Winter V, Kølvrå S, Bolund L, Gregersen N (1994) Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency due to heterozygosity for the common mutation and an allele resulting in low levels of MCAD mRNA. *J Inher Metab Dis* 17:275-278.
  18. Bross P, Jensen TG, **Andresen BS**, Kjeldsen M, Nandy A, Kølvrå S, Ghisla S, Rasched I, Bolund L, Gregersen N (1994) Characterization of wild-type human medium-chain acyl-CoA dehydrogenase (MCAD) and mutant enzymes present in MCAD-deficient patients by two-dimensional gel electrophoresis: evidence for posttranslational modification of the enzyme. *Biochem Med Metab Biol* 52:36-44.
  19. Jensen HK, Jensen TG, Jensen LG, Hansen PS, Kjeldsen M, **Andresen BS**, Nielsen V, Meinertz H, Hansen AB, Bolund L, Færgeman O, Gregersen N (1994) Characterization of a disease-causing Glu<sup>119</sup>-Lys mutation in the low density lipoprotein receptor gene in two Danish families with heterozygous Familial Hypercholesterolemia. *Hum Mutat* 4:102-113.
  20. Kristensen MJK, Bross P, **Andresen BS**, Kmoch S and Gregersen N (1994) A prevalent amino acid polymorphism at position 209 in the short-chain acyl-CoA dehydrogenase (SCAD) gene. *Hum Mol Genet* 3:1711.
  21. Gregersen N, Winter V, Jensen PKA, Holmskov A, Kølvrå S, **Andresen BS**, Christensen E, Bross P, Lundemose J and Gregersen M (1995) Prenatal diagnosis of medium-chain acyl-coA dehydrogenase (MCAD) deficiency in a family with a fatal case of sudden unexpected death in childhood. *Prenatal diagnosis* 15:82-86.
  22. Jensen TG, Bross P, **Andresen BS**, Lund TB, Kristensen TJ, Jensen UB, Winter V, Kølvrå S, Gregersen N and Bolund L (1995) Comparison between medium-chain acyl-CoA dehydrogenase (MCAD) mutant proteins overexpressed in bacterial and mammalian cells. *Hum Mutat* 6:226-231.
  23. Sandvej K, Peh SC, **Andresen BS**, Pallesen G (1994) Identification of potential hotspots in the carboxy-terminal part of the EBV-BNLF-1 gene in both malignant and benign EBV associated diseases: High frequency of 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. *Blood* 84:4053-4060.
  24. Bross P, Jespersen C, Jensen TG, **Andresen BS**, Kølvrå S, Bolund L and Gregersen N (1995) Effects of two mutations detected in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient patients on folding, oligomer assembly, and stability of MCAD enzyme. *J Biol Chem* 270:10284-10290.
  25. Corydon MJ, Gregersen N, Lehnert W, Ribes A, Rinaldo P, Kmoch S, Christensen E, Kristensen TJ, **Andresen BS**, Bross P, Winter V, Martinez G, Neve S, Jensen TG, Bolund L and Kølvrå S (1996) Ethylmalonic aciduria is associated with an amino acid variant of short-chain acyl-Coenzyme A dehydrogenase. *Pediatr Res* 39:1-8.
  26. Bross P, **Andresen BS**, Knudsen I, Kruse T, and Gregersen N (1995) Human ClpP protease: cDNA sequence, tissue-specific expression and chromosomal assignment of the gene. *FEBS letters* 377:249-252.
  27. **Andresen BS**, Bross P, Vianey-Saban C, Divry P, Zobot MT, Roe CR, Nada MA, Byskov A, Kruse TA, Kristiansen K, Neve S, Corydon MJ, Gregersen N (1996) Cloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of 9 different mutations within this gene. *Hum Mol Genet* 5:461-472 and 1390.
  28. Jensen TG, **Andresen BS**, Jensen HK, Jensen LG, Heath F, Pedersen S, Nielsen V, Jensen UB, Lund TB, Gregersen N, Kølvrå S and Bolund L (1996) Rapid characterization of mutations in the low density lipoprotein receptor (LDLR) gene by overexpression in COS cells. *German Journal of Gastroenterology* 34(suppl. 3) 9-11.
  29. **Andresen BS**, Vianey-Saban C, Bross P, Divry P, Roe CR, Nada MA, Knudsen I and Gregersen N (1996) The mutational spectrum in very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. *J Inher Metab Dis* 19:169-172.
  30. Jensen HK, Jensen TG, Færgeman O, Jensen LG, **Andresen BS**, Corydon MJ, Andreasen PH, Hansen PS, Heath F, Bolund L, Gregersen N (1997) Two mutations in the same low density lipoprotein receptor allele act in synergy to reduce receptor function in heterozygous familial hypercholesterolemia. *Hum Mut* 9:437-444.
  31. Jensen HK, Holst H, Jensen LG, Jørgensen MM, Andreasen PH, Jensen TG, **Andresen BS**, Heath F, Hansen PS, Neve S, Kristiansen K, Færgeman O, Kølvrå S, Bolund L, Gregersen N (1997) A common W556S mutation in the LDL receptor gene of Danish patients with familial hypercholesterolemia encodes a transport-defective protein. *Atherosclerosis* 131:67-72.

32. **Andresen BS**, Bross P, Udvari S, Kirk J, Gray RGF, Kmock S, Chamoles N, Knudsen I, Winter V, Kølvrå S, Bolund L, Wilcken B, Yokota I, Harpey JP, Hart K, Packman S, Saudubray JM, Hale DE, Bolund L, Kølvrå S, Gregersen N (1997) The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients - Is there a correlation between genotype and phenotype? *Hum Mol Genet* **6**:695-708.
33. Sandvej K, Gratama JW, Munch M, Zhou XG, Bolhuis RLH, **Andresen BS**, Gregersen N, Hamilton-Dutoit S (1997) Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: Identification of four variants among wild-type EBV isolates. *Blood* **90**:323-330.
34. Corydon MJ, **An-d-r-e-sen BS**, Bross P, Kruse TA, Kjeldsen M, Andreassen PH, Eiberg H, Kølvrå S and Gregersen N (1997) Structural organization of the human short-chain acyl-CoA dehydrogenase gene. *Mammalian Genome* **8**:922-926.
35. Smelt G, Poorthuis BJHM, Onkenhout W, Scholte HR, **Andresen BS**, Gregersen N, VanDuinen SG, Wintzen AR (1998) Adult onset very-long-chain acyl-Coenzyme A dehydrogenase deficiency. Clinical, morphological, biochemical and genetic features. *Ann. Neurology* **43**:540-544.
36. Gregersen N, Winter V, Corydon MJ, Corydon TJ, Ribes A, Martinez G, Bennett MJ, Vianey-Saban C, Bhala A, Hale DE, Rinaldo P, Lehnert W, Knoch S, **Andresen BS**, Bross P, Bolund L and Kølvrå S (1998) Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: One of the variant alleles, 511C>T, is present at an unexpectedly high frequency in the normal population, as was the case for 625G>A, together conferring susceptibility to ethylmalonic aciduria. *Hum Mol Genet* **7**:619-627.
37. Udvari S, Bross P, **Andresen BS**, Gregersen N, Engel PC (1999) Biochemical characterisation of mutations of human medium-chain acyl-CoA dehydrogenase. *Adv Exp Med Biol.* **466**:387-93.
38. Udvari S, Bross P, **Andresen BS**, Gregersen N, Engel PC (1998) Mutations of human medium-chain acyl-CoA dehydrogenase. *Biochem Soc Trans.* **26**(1):S65.
39. Scholte HR, VanCoster RNA, deJonge PC, Poorthuis BJHM, Jeneson JAL, **Andresen BS**, Gregersen N, deKlerk JBC and Busch HFM (1999) Myopathy in very-long-chain acyl-Coenzyme A dehydrogenase deficiency: clinical and biochemical differences with the fatal cardiac phenotype. *Neuromuscular Disorders* **9**:313-319.
40. Sørensen CB, Ladekær-Mikkelsen AS, **An-d-r-e-sen BS**, Brandrup F, Veien NK, Buus SK, Anton-Lamprecht I, Kruse TA, Jensen PKA, Eiberg H, Bolund L, Gregersen N (1999) Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with Epidermolysis Bullosa Simplex: Correlation between genotype and phenotype. *J Invest Dermatol* **112**:184-90.
41. **Andresen BS**, Olpin S, Kvittingen EA, Auguostodes-Savvopoulou P, Lindhout D, Halley DJ, Vianey-Saban C, Wanders RJA, Ijlst L, Schroeder LD, Bolund L, Gregersen N (1999) DNA-based prenatal diagnosis for VLCAD deficiency. *J Inher Metab Dis* **22**:281-285.
42. **Andresen BS**, Olpin S, Poorthuis B, Scholte HR, Vianey-Saban C, Wanders RJA, Ijlst L, Morris A, Pourfazam M, Bartlett K, Bross P, Lund H, Corydon TJ, Schrøder LD, Winter V, Bolund L, Gregersen N (1999) It is possible to correlate genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. *Am J Hum Genet* **64**:479-494.
43. Siggaard C, Rittig S, Corydon TJ, Andreassen PH, Jensen TG, **Andresen BS**, Robertson GL, Gregersen N, Bolund L, Pedersen EB (1999) Clinical and molecular evidence of abnormal processing and trafficking of the vasopressin preprohormone in a large kindred with familial neurohypophyseal diabetes insipidus due to a signal peptide mutation. *J Clin Endocrinol Metab.* **84**:2933-41.
44. Bross P, Pedersen P, Winter V, Nyholm M, Nagstrup Johansen B, Olsen RKJ, Corydon MJ, **Andresen BS**, Eiberg H, Kølvrå S, Gregersen N (1999) A polymorphic variant in the human electron transfer flavoprotein a-chain (a-171) displays decreased thermal stability and is overrepresented in very-long-chain acyl-CoA dehydrogenase deficient patients with mild childhood presentation. *Molecular Genetics and Metabolism* **67**:138-147.
45. Brandt-Sørensen C, Ladekær-Mikkelsen AS, **Andresen BS**, Brandrup F, Veien NK, Buus SK, Anton-Lamprecht I, Kruse TA, Jensen PKA, Eiberg H, Bolund L, Gregersen N (1999) Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis Bullosa Simplex: Korrelation mellem genotype og fænotype i danske patienter. *Ugeskrift for læger* **162**:1873-1876.
46. Jensen PKA, Brandt-Sørensen C, **Andresen BS**, Brandrup F, Veien NK, Buus SK, Gregersen N, Bolund L (1999) Keratinsygdomme. *Ugeskrift for læger* **162**:1867-1872.
47. Bross P, Corydon TJ, **Andresen BS**, Jørgensen MM, Bolund L, Gregersen N (1999) Protein misfolding and degradation in genetic diseases. *Hum Mutat* **14**:186-198.
48. Merinero B, Pascual Pascual SI, Perez-Cerda C, Gangoiti J, Castro M, Garcia MJ, Pascua Castroviejo I, Vianey-Saban C, **Andresen B**, Gregersen N, Ugarte M (1999) Adolescent myopathic presentation in two sisters with very long-chain acyl-CoA dehydrogenase deficiency. *J Inher Metab Dis* **22**:802-810.
49. Gregersen N, Bross P, Jørgensen MM, Corydon TJ, **Andresen BS** (2000) Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders. *J Inher Metab Dis* **23**:441-447.
50. Sandvej K, **Andresen BS**, Zhou XG, Gregersen N, Hamilton-Dutoit S (2000) Analysis of the Epstein-Barr virus (EBV) latent membrane binding protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against a variant with mutations in the LMP-1 ATF1/CREB-1 binding site. *Mol Pathol* **53**:280-288.
51. Gregersen N, **Andresen BS**, Corydon MJ, Corydon TJ, Olsen RK, Bolund L, Bross P (2001) Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. *Hum Mutat* **18**:169-89.
52. Gregersen N, **Andresen BS**, Bross P (2000) Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations. *Eur J Pediatr* **159** Suppl 3:S213-8.
53. **Andresen BS**, Corydon TJ, Wilsbech M, Bross P, Schroeder LD, Hindkær TF, Bolund L, Gregersen N (2000) Characterization of the mouse ClpP protease cDNA, gene and protein. *Mammalian Genome* **11**:275-280.

54. Spiekerkotter U, Schwahn B, Korall H, Trefz FK, **Andresen BS**, Wendel U (2000) Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: monitoring of treatment by carnitine/acylcarnitine analysis in blood spots. *Acta Paediatr.* **89**:492-495.
55. Corydon TJ, Jespersgård C, Wilsbech M, **Andresen BS**, Børnglum AD, Gregersen N, Bross P (2000) Human and mouse ClpX orthologues: cDNA sequences, structure of the human gene, tissue-specific expression, chromosomal mapping, and subcellular localisation. *Mammalian Genome* **11**:299-305.
56. **Andresen BS**, Christensen E, Corydon TJ, Bross P, Pilgaard B, Simonsen H, Knudsen I, Schroeder LD, Gregersen N, Skovby F (2000) Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase (SBCAD) deficiency: Identification of a new enzyme defect, resolution of its molecular basis and evidence for distinct acyl-CoA dehydrogenases in isoleucine and valine metabolism. *Am J Hum Genet* **67**:1095-1103.
57. Scholte HR, VanCoster RNA, deJonge PC, Poorthuis BJHM, Jeneson JAL, **Andresen BS**, Gregersen N, deKlerk JBC and Busch HFM (2000) Myopathy in very-long-chain acyl-Coenzyme A dehydrogenase deficiency. Clinical and biochemical differences with the fatal cardiac phenotype. *Neurology (Review series)* **2**:15-16.
58. Gregersen N, Bross P, **Andresen BS**, Pedersen CB, Corydon TJ, Bolund L (2001) The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders. *J Inher Metab Dis.* **24**:189-212.
59. Touma EH, Rashed MS, Vianey-Saban C, Sakr A, Divry P, Gregersen N, **Andresen BS** (2001) A severe genotype with favourable outcome in very long chain acyl-CoA dehydrogenase deficiency. *Archives of Disease in Childhood* **84**:58-60
60. Merinero B, Pascual SI, Perez-Cerda C, Gangoiti J, Castro M, Garcia MJ, Castroviejo IP, Vianey-Saban C, **Andresen B**, Gregersen N, Ugarte M (2001) Adolescent myopathic pre-sen-tation in two sisters with very long chain acyl-CoA dehydrogenase deficiency. In: Wahl-gren NG (ed) Review Series: Neurology. Charles Garza, Stockholm, pp 22-26.
61. **Andresen BS**, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless S, Frazier D, Udvari S, Bross P, Knudsen I, Banas R, Chace D, Engel P, Naylor EW, Gregersen N (2001) The spectrum of medium-chain acyl-coa dehydrogenase (MCAD) mutations in newborns identified by MS/MS based prospective newborn screening is different from that observed in patients with clinical symptoms – Identification and characterization of a new prevalent mutation that results in mild MCAD deficiency. *Am J Hum Genet* **68**:1408-18.
62. Nguyen TV, **Andresen BS**, Corydon TJ, Ghisla S, Abd-El Razik N, Mohsen AAW, Cederbaum SD, Roe DS, Roe CR, Lench NJ, Vockley J (2002) Identification of isobutyryl-CoA dehydrogenase and its deficiency in humans. *Molecular Genetics and Metabolism* **77**: 68-79.
63. Curcoy A, Olsen RK, Ribes A, Trenchs V, Vilaseca MA, Campistol J, Osorio JH, **Andresen BS**, Gregersen N (2003) Late onset form of beta-electron transfer flavoprotein deficiency. *Mol Genet Metab.* **78**:247-249.
64. Matern D, He M, Berry SA, Rinaldo P, Whitley CB, Madsen PP, van Calcar SC, Lussky RC, **Andresen BS**, Wolff JA, Vockley J. (2003) Prospective diagnosis of 2-methylbutyryl-CoA dehydrogenase deficiency in the Hmong population by newborn screening using tandem mass spectrometry. *Pediatrics.* **112**:74-78.
65. Olsen RK, **Andresen BS**, Christensen E, Bross P, Skovby F, Gregersen N. (2003) Clear relationship between ETF/ETFHD genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. *Hum Mutat.* **22**:12-23.
66. Sørensen CB, **Andresen BS**, Jensen UB, Jensen TG, Jensen PKA, Gregersen N, Bolund L (2003) Functional testing of keratin 14 mutant proteins associated with the three major subtypes of epidermolysis bullosa simplex. *Experimental Dermatology* **12**:472-479.
67. Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, Leonard JV, Land JM, **Andresen BS**, Morris AA, Muntoni F, Turnbull D, Pourfarzam M, Rahman S, Pollitt RJ (2003) Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. *J Inher Metab Dis.* **26**(6):543-557.
68. Gregersen N, Bross P, **Andresen BS** (2004) Genetic defects in fatty acid  $\beta$ -oxidation and acyl-CoA dehydrogenases - Molecular pathogenesis and genotype-phenotype relationships. *Eur J Biochemistry* **271**:470-482.
69. Korman SH, Gutman A, Brooks R, Sinnathamby T, Gregersen N, **Andresen BS** (2004) Homozygosity for a severe novel medium-chain acyl-CoA dehydrogenase (MCAD) mutation IVS3-1G>C that leads to introduction of a premature termination codon by complete missplicing of MCAD mRNA, and is associated with phenotypic diversity ranging from sudden neonatal death to asymptomatic status. *Molecular Genetics and Metabolism.* **82**:121-129.
70. Olsen RKJ, Pourfarzam M, Morris AAM, Dias RC, Knudsen I, **Andresen BS**, Gregersen N, Olpin SE (2004) Lipid storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenation deficiency. *J Inher Metab Dis* **27**(5):671-678.
71. O'Reilly L, Bross P, Corydon TJ, Olpin SE, Hansen J, Kenney JM, McCandless S, Frazier D, Winter V, Gregersen N, Engel PC, **Andresen BS** (2004) The Y42H mutation in medium-chain acyl-CoA dehydrogenase (MCAD), which is prevalent in babies identified by MS/MS based newborn screening, is temperature sensitive. *FEBS J* **271**(20):4053-63.
72. Korman SH, **Andresen BS**, Zeharia A, Gutman A, Boneh A, Pitt J (2005) 2-Ethylhydracrylic aciduria in Short/branched-chain acyl-CoA dehydrogenase deficiency: Application to diagnosis and implications for the R-pathway of isoleucine oxidation *Clinical Chemistry* **51**(3):610-617.
73. Olsen RK, **Andresen BS**, Christensen E, Mandel H, Skovby F, Nielsen JP, Knudsen I, Vianey-Saban C, Simonsen H, Gregersen N (2005) DNA-based prenatal diagnosis for severe and variant forms of multiple acyl-CoA dehydrogenation deficiency. *Prenat Diagn.* **25**(1):60-64.
74. Olpin SE, Clark S, **Andresen BS**, Bischoff C, Olsen RKJ, Gregersen N, Chakrapani A, Downing M, Manning NJ, Sharrard M, Bonham JR, Muntoni F, Turnbull D, Pourfarzam M (2005) Biochemical, clinical and molecular findings in defects of mitochondrial trifunctional protein *J Inher Metab Dis* **28**(4):533-44.
75. O'Reilly L, **Andresen BS**, Engel PC (2005) Two novel variants of medium chain acyl-CoA dehydrogenase (ACADM); K364R, a folding mutation, and R256T, a catalytic-site mutation resulting in a well-folded but totally inactive protein. *FEBS Journal* **272**:4549-4557.

76. Madsen PP, Kibæk M, Roca X, Sachidanandam R, Krainer AR, Christensen E, Steiner R, Gibson KM, Corydon TJ, Knudsen I, Wanders RJA, Ruitter JPN, Gregersen N, **Andresen BS** (2006) Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3+3A>G mutation that causes exon skipping. *Human Genetics* 118(6):680-690.
77. Waddell L, Wiley V, Carpenter K, Bennetts B, Angel L, **Andresen BS**, Wilcken B (2006) Medium-chain acyl-CoA dehydrogenase deficiency: Genotype – Biochemical phenotype correlations. *Mol Genet Metab* 87(1):32-39.
78. Boneh A, **Andresen BS**, Gregersen N, Ibrahim M, Tzanakos N, Peters H, Yapliito-Lee J, Pitt JJ (2006) VLCAD deficiency: Pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. *Mol Genet Metab* 88(2):166-70.
79. Pedersen CB, Bischoff C, Christensen E, Simonsen H, Lund A, Young SP, Koeberl DD, Millington DS, Roe C, Roe D, Keppen LD, Stein Q, Knudsen I, Gregersen N, **Andresen BS** (2006) Variations in IBD (ACAD8) in children with elevated C4-carnitine detected by tandem mass spectrometry newborn screening. *Pediatric Research* 60:315-320.
80. Maydan G, **Andresen BS**, Madsen PP, Zeigler M, Raas-Rothschild A, Zlotogorski A, Gutman A, Korman SH (2006) TAT gene analysis in three Palestinian kindreds with oculocutaneous tyrosinemia II: characterization of a silent exonic transversion that causes complete missplicing by exon 11 skipping *J Inher Metab Dis* 29:620-626.
81. Nielsen KB, Sørensen S, Cartegni L, Corydon TJ, Doktor TK, Schroeder LD, Reinert LS, Elpeleg ON, Krainer AR, Gregersen N, Kjems J, **Andresen BS** (2007) Seemingly neutral polymorphic variants may confer immunity to splicing inactivating mutations *Am J Hum Genet* 80(3):416-32.
82. Kanavin OJ, Jellum E, Woldseth B, Tvedt B, **Andresen BS**, Strømme P (2007) 2-methylbutyryl-CoA dehydrogenase deficiency associated with autism and mental retardation: a case report. *J Med Case Reports* 1(1):98 PMID: 17883863.
83. Olsen RKJ, Olpin SE, **Andresen BS**, Miedzybrodska Z, Pourfarzam M, Merinero B, Frerman FE, Beresford MW, Dean JCS, Cornelius N, Andersen O, Oldfors A, Holme E, Gregersen N, Turnbull DM, Morris AAM (2007) ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. *Brain* 130(Pt 8):2045-54.
84. Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, **Andresen BS**, Yamaguchi S, Mandel H, Fukao T, Ruitter JPN, Wanders RJA, McAndrew R, Kim JJ, Bastin J (2007) Genetic basis for correction of Very Long Chain Acyl-CoA Dehydrogenase deficiency by bezafibrate in patient fibroblasts: towards a genotype-based therapy. *Am J Hum Genet* 81(6):1133-43.
85. Sass JO, Ensenauer R, Röschinger W, Reich H, Steuerwald U, Schirrmacher O, Engel K, Häberle J, **Andresen BS**, Mégarbané A, Lehnert W, Zschocke J (2008) 2-Methylbutyryl-Coenzyme A Dehydrogenase Deficiency: Functional and Molecular Studies on a Defect in Isoleucine Catabolism. *Molecular Genetics and Metabolism* 93(1):30-5.
86. Roca X, Olson AJ, Rao AR, Enerly E, Kristensen VN, Borresen-Dale AL, **Andresen BS**, Krainer AR, Sachidanandam R (2008) Disease-causing mutations at 5' splice sites and comparative genomics help identify features determining splice-site efficiency. *Genome Research* 18(1):77-87.
87. Gregersen N, **Andresen BS**, Pedersen CB, Olsen RKJ, Corydon TJ, Bross P (2008) Mitochondrial fatty acid oxidation defects – remaining challenges. *J Inher Metab Dis* 31:643-57.
88. Maegawa GHB, Poplawski N, **Andresen BS**, Olpin SE, Nie G, Clarke JTR, Teshima I (2008) Interstitial deletion of 1p22.2-p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with developmental delay. *Am J Med Genet (Part A)* 146A:1581-1586.
89. Horvath GA, Davidson AGF, Stockler-Ipsiroglu SG, Lillquist YP, Waters PJ, Olpin S, **Andresen BS**, Palaty J, Nelson J, Vallance H (2008) Newborn screening for MCAD Deficiency. Experience of the first three years in British Columbia, Canada. *Canadian Journal of Public Health* 99(4):276-280.
90. Pedersen CB, Kølvråa S, Kølvråa A, Stenbroen V, Kjeldsen M, Ensenauer R, Tein I, Matern D, Rinaldo P, Vianey-Saban C, Ribes A, Lehnert W, Christensen E, Corydon TJ, **Andresen BS**, Vang S, Bolund L, Vockley J, Bross P, Gregersen N (2008) The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. *Human Genetics* 124(1):43-56.
91. Khalid JM, Oerton J, Cortina-Borja M, **Andresen BS**, Besley G, Dalton N, Downing M, Foo Y, Green A, Henderson M, Leonard J, Dezateaux C - On behalf of the UK Collaborative Study of Newborn Screening for MCADD (2008) Ethnic-specific birth prevalence of c.985A>G homozygous Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD): results from screening ~ 1.1 million newborn infants. *Journal of Medical Screening*. 15(3):112-117.
92. **Andresen BS**, Orton J, Leonard J, Dezateaux C et al. (2009) Spectrum of medium chain acyl CoA dehydrogenase (MCAD) mutations identified from newborn screening of 1.56 million infants from the UK. *Mol. Genet. Metab.* 98:3-4.
93. Laforêt P, Acquaviva-Bourdain C, Rigal O, Brivet M, Penisson-Besnier I, Chabrol B, Chaigne D, Boespflug-Tanguy O, Laroche C, Bedat-Millet AL, Behin A, Delevaux I, Lombès A, **Andresen BS**, Eymard B, Vianey-Saban C (2009) Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-coenzyme A dehydrogenase (VLCAD) deficiency. *Neuromuscular Disorders* 19(5):324-9.
94. Olsen RKJ, Dobrowolski SF, Kjeldsen M, Hougaard DM, Simonsen H, Gregersen N, **Andresen BS** (2010) High resolution amplicon melting analysis, A simple and effective method for reliable mutation scanning and frequency studies in the *ACADVL* gene. *J Inherited Metabolic Disease* 33:247–260.
95. Piekutowska-Abramczuk D, Olsen RK, Wierzbza J, Popowska E, Jurkiewicz D, Ciara E, Ołtarzewski M, Gradowska W, Sykut-Cegielska J, Krajewska-Walasek M, **Andresen BS**, Gregersen N, Pronicka E (2010) A comprehensive HADHA c.1528G>C frequency study reveals high prevalence of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency in Poland. *J Inherited Metabolic Disease* 33:Suppl 3:S373-7.
96. Homolova K, Zavadakova P, Doktor TK, Schroeder LD, Kozich V, **Andresen BS** (2010) The prevalent intronic c.903+469T>C mutation in the *MTRR* gene creates an SF2/ASF binding ESE, which leads to pseud exon activation and causes the cblE type of homocystinuria. *Human Mutation* 31:437–444.
97. Dessein AF, Fontaine M, **Andresen BS**, Gregersen N, Brivet M, Rabier D, Napuri-Gouel S, Dobbelaere D, Mention-Mulliez K, Martin-Ponthieu A, Briand G, Millington DS, Vianey-Saban C, Wanders RJA, Vamecq J (2010). A novel

- mutation of the *ACADM* gene (c.145C>G) associated with the common c.985A>G mutation on the other *ACADM* allele causes mild MCAD deficiency: a case report. *Orphanet J Rare Dis*, 5:26.
98. Dobrowolski SF, Andersen HS, Doktor TK, **Andresen BS** (2010) The PAH c.30C>G synonymous variation (p.G10G) creates a common exonic splicing silencer. *Molecular Genetics and Metabolism* 100:316–323.
99. Sykut-Cegielska J, Gradowska W, Piekutowska-Abramczuk D, **Andresen BS**, Oisen RKJ, Ołtarzewski M, Pronicki M, Pajdowska M, Bogdańska A, Jabłonska E, Radomycka B, Kusmierska K, Krajewska-Walasek M, Gregersen N, Pronicka E. (2011) Urgent metabolic service improves survival in long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency detected by symptomatic identification and pilot newborn screening. *J Inherited Metabolic Disease* 34(1):185–95.
100. Doktor TK, Schröder LD, Jensen AV, Palmfeldt J, Andersen HS, Gregersen N, **Andresen BS** (2011) *SMN2* exon 7 splicing is inhibited by binding of hnRNPA1 to a common ESS motif that spans the 3' splice site. *Human Mutation* 32(2):220–30.
101. Oerton J, Khalid JM, Besley G, Green A, **Andresen BS**, Leonard J, Dezateu C - On behalf of the UK Collaborative Study of Newborn Screening for MCADD (2011) Newborn screening for Medium Chain Acyl CoA Dehydrogenase Deficiency in a multi-ethnic population: Prevalence, predictive value and test validity based on 1.5 million screened babies. *J Medical Screening* 18:173–181.
102. Couce ML, Castiñeiras DE, Moure JD, Cocho JA, Sánchez-Pintos P, García-Villoria J, Quelhas D, Gregersen N, **Andresen BS**, Ribes A, Fraga JM (2011) Relevance of expanded neonatal screening of medium-chain acyl co-a dehydrogenase deficiency: outcome of a decade in galicia (Spain). *JIMD Rep.* 2011;1:131-6. doi: 10.1007/8904\_2011\_28.
103. Masuda A, Andersen HS, Doktor TK, Okamoto T, Ito M, **Andresen BS**, Ohno K (2012) Global analysis of RNA-binding sites of CUGBP1 and MBNL1 reveals their preferential binding to 3' UTRs and a new role for MBNL1 in mRNA decay. *Scientific Reports* 2:209.
104. **Andresen BS**, Lund AM, Hougaard DM, Christensen E, Gahrn B, Christensen M, Bross P, Vested A, Simonsen H, Skogstrand K, Olpin S, Brandt NJ, Skovby F, Nørgaard-Pedersen B, Gregersen N on behalf of the Danish newborn screening group (2012) MCAD deficiency in Denmark. *Molecular Genetics and Metabolism* 106:175–188.
105. Heintz C, Dobrowolski SF, Andersen HS, Demirkol M, Blau N, **Andresen BS** (2012) Splicing of phenylalanine hydroxylase (*PAH*) exon 11 is vulnerable - Molecular pathology of mutations in *PAH* exon 11. *Molecular Genetics and Metabolism* 106:403–411.
106. Lund AM, Hougaard DM, Simonsen H, **Andresen BS**, Christensen M, Dunø M, Skogstrand K, Olsen RKJ, Jensen UG, Cohen A, Larsen N, Saugmann-Jensen P, Gregersen N, Brandt NJ, Christensen E, Skovby F, Nørgaard-Pedersen B (2012) Biochemical screening of 504.049 newborns in Denmark, the Faroe Islands and Greenland – experience and development of a routine programme for expanded newborn screening. *Mol Genet Metab* 107(3):281–93.
107. Borch L, Lund AM, Wibrand F, Christensen E, Søndergaard C, Gahrn B, Hougaard DM, **Andresen BS**, Gregersen N, Olsen RK (2012) Normal levels of plasma free carnitine and acylcarnitines in follow-up samples from a presymptomatic case of carnitine palmitoyl transferase 1 (CPT1) deficiency detected through newborn screening in Denmark. *J Inherited Metabolic Disease Rep* 3:11–5.
108. Searle C, **Andresen BS**, Wraith E, Higgs J, Gray D, Mills A, KE Allen, Hobson E (2013) A large intragenic deletion in the *ACADM* gene can cause MCAD deficiency but is not detected on routine sequencing. *J Inherited Metabolic Disease Rep* DOI 10.1007/8904\_2013\_216.
109. Bruun GH, Doktor TK, **Andresen BS** (2013) A synonymous polymorphic variation in *ACADM* exon 11 affects splicing efficiency and may affect betaoxidation. *Mol Genet Metab* 10:122–128.
110. Risom L, Christoffersen L, Daugaard J, Hove H, Andersen HS, **Andresen BS**, Kreiborg S, Dunø M (2013) Identification of six novel *PTH1R* mutations in families with a history of primary failure of tooth eruption. *PLoS ONE* 8(9):e74601. doi:10.1371/journal.pone.0074601.
111. Olsen RKJ, Brøner S, Sabaratnam R, Doktor TK, Andersen HS, Bruun GH, Gahrn B, Stenbroen V, Olpin SE, Dobbie A, Gregersen N, **Andresen BS** (2014) The ETFDH c.158A>G variant disrupts the balanced interplay of ESE- and ESS-binding proteins thereby causing missplicing and multiple acyl-CoA dehydrogenation deficiency. *Human Mutation* 35(1):86–95.
112. Doktor TK, Schröder LD, Brøner S, Andersen HS, Kitewska A, Sørensen CB, **Andresen BS** (2014) Absence of an ISS in porcine *Smn1* intron 7 confers immunity to the exon skipping mutation in human *SMN2*. *PLoS ONE*.9(6):e98841. doi: 10.1371/journal.pone.0098841. eCollection 2014.
113. Brown A, Crowe L, **Andresen BS**, Anderson V, Boneh A (2014) Neurodevelopmental profiles of children with very long chain acyl-CoA dehydrogenase deficiency diagnosed by newborn screening. *Mol Genet Metab*.113(4):278–82.
114. Aksglaede L, Christensen M, Olesen JH, Dunø M, Olsen RKJ, **Andresen BS**, Hougaard DM, Lund AM (2015) Abnormal newborn screening in a healthy infant of a mother with undiagnosed medium-chain acyl-CoA dehydrogenase deficiency. *JIMD Rep* 23:67–70. PMID: 25763512.
115. Palhais B, Præstegaard VS, Sabaratnam R, Doktor TK, Lutz S, Burda P, Suormala T, Baumgartner M, Fowler B, Bruun GH, Andersen HS, Kozich V, **Andresen BS** (2015) Antisense mediated blocking of an ESE created by the prevalent intronic c.903+469T>C *MTRR* mutation corrects splicing and restores enzyme activity in patient cells. *Nucleic Acids Research* 3(9): 4627–4639.
116. Djouadi F, Habarou F, Le Bachelier C, Ferdinandusse S, Schlemmer D, Benoist JF, Boutron A, **Andresen BS**, Visser G, de Lonlay P, Olpin S, Fukao T, Yamaguchi S, Strauss AW, Wanders RJA, Bastin J (2016) Mitochondrial trifunctional protein deficiency in human cultured fibroblasts: effects of bezafibrate. *J Inher Metab Dis* 39(1): 47–58.
117. Hartung AM, Swensen J, Uriz IE, Guerra B, Lapin M, Kristjansdottir K, Bang JMV, Petersen USS, Dobrowolski SF, Carey JC, Yi P, Calhoun A, Vaughn C, Andersen HS, Larsen MR, Dyrskjøt L, Stevenson DA, **Andresen BS**(2016) The splicing efficiency of activating HRAS mutations can determine Costello syndrome phenotype and frequency in cancer. *PLoS Genet* 12(5): e1006039.

118. Stevenson DA, Schill L, Schoyer L, **Andresen BS**, Bakker A, Bayrak-Toydemir P, Burkitt-Wright E, Chatfield K, Eleftheriou F, Elgersma Y, Fisher MJ, Franz D, Gelb B, Goriely A, Gripp KW, Hardan A, Keppler-Noreuil K, Kerr B, Korf B, Leoni C, McCormick F, Plotkin S, Rauen KA, Reilly K, Roberts A, Sandler A, Siegel D, Walsh K, Widemann BC (2016) The Fourth International Symposium on Genetic Disorders of the RAS/MAPK Pathway. *Am J Med Genet* 118(4):282-287.
119. Bruun GH, Doktor TK, Borch J, Masuda A, Krainer AR, Ohno K, **Andresen BS** (2016) Global identification of hnRNP A1 binding sites for splice switching oligonucleotide-based therapy. *BMC Biology* 14(1):54.
120. Evans M, **Andresen BS**, Nation J, Boneh A (2016) VLCAD deficiency: Follow-up and outcome of patients diagnosed through newborn screening in Victoria. *Mol Genet Metab*. 118(4): 282-287.
121. Palhais B, Dembic M, Sabaratnam R, Nielsen KS, Doktor TK, Bruun GH, **Andresen BS** (2016) The prevalent deep intronic c.639+919 G>A GLA mutation causes pseudoexon activation and Fabry disease by abolishing the binding of hnRNPA1 and hnRNP A2/B1 to a splicing silencer. *Mol Genet Metab*. 119: 258-269.
122. Santra S, Macdonald A, Preece MA, Olsen RK, **Andresen BS** (2017) Long-term outcome of Isobutyryl-CoA dehydrogenase deficiency diagnosed following an episode of ketotic hypoglycaemia. *Mol Genet Metab Rep*. 10: 28–30.
123. Doktor TK, Hua Y, Andersen HS, Brøner S, Liu YH, Wieckowska A, Dembic M, Bruun GH, Krainer AR, **Andresen BS** (2017) RNA sequencing of a mouse-model of Spinal Muscular Atrophy reveals tissue-wide changes in splicing of U12-dependent introns. *Nucleic Acids Research* 45(1):395-416.
124. Olpin SE, Clark S, Dalley J, **Andresen BS**, Croft J, Scott C, Khan A, Kirk R, Sparks R, Chard M, Chan A, Glamuzina E, Bastin J, Manning NJ, Pollitt RJ (2017) Fibroblast Fatty-Acid Oxidation Flux Assays Stratify Risk in Newborns with Presumptive-Positive Results on Screening for Very-Long Chain Acyl-CoA Dehydrogenase Deficiency. *Int J Neonatal Screen* 3:2.
125. Heintz C, Doktor TK, Lanjuin A, Escoubas C, Zhang Z, Weir HJ, Dutta S, Silva-Garcia CG, Bruun GH, Morante I, Hoxhaj G, Manning BD, **Andresen BS**, Mair WB (2017) Splicing Factor 1 Modulates Dietary Restriction and TORC1 Pathway Longevity in *C. elegans*. *Nature* 541(7635): 102-106.
126. Mosegaard S, Bruun GH, Flyvbjerg KF, Bliksrud YT, Gregersen N, Dembic M, Annexstad E, Tangeraas T, Olsen RKJ, **Andresen BS** (2017) An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. *Molecular Genetics and Metabolism* 122(4): 182-188.
127. Doktor TK, Heintz C, **Andresen BS**, Mair WB (2018) Alternative splicing analysis of RNA-seq data using SAJR. *Protocol Exchange*. doi:10.1038/protex.2018.029.
128. Martínez-Pizarro A, Dembic M, Pérez B, **Andresen BS\***, Desviat LR\* (2018) Intronic PAH gene mutations cause a splicing defect by a novel mechanism involving U1snRNP binding downstream of the 5' splice site. *PLoS Genet* 14(4):e1007360 \*Shared senior author and correspondence.
129. Bruun GH, Bang JMV, Christensen LL, Brøner S, Petersen US, Guerra B, Grønning A, Doktor TK, **Andresen BS** (2018) Blocking of an intronic silencer completely rescues IKBKAP exon 20 splicing in familial dysautonomia patient cells. *Nucleic Acids Research* 46:7938–7952.
130. Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, **Andresen BS**, Cavé H, Ellis M, Fruchtman SM, Gelb B, Gibson C, Gripp KW, Hefner E, Huang W, Itkin M, Kerr B, Linardic C, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites E, Stork P, Sun C, Therrien M, Ullian E, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F (2018) 5th International RASopathies Symposium: When Development and Cancer Intersect. *Am J Med Genet Part A* 172: 2924-2929.
131. Dembic M, Andersen HS, Bastin J, Doktor TK, Corydon TJ, Sass JO, Costa AL, Djouadi F, **Andresen BS** (2019) Next Generation Sequencing of RNA reveals novel targets of Resveratrol with possible implications for Canavan disease. *Molecular Genetics and Metabolism* 126:64-76.
132. Grønnskov K, Jespersgaard C, Bruun GH, Harris P, Brøndum-Nielsen K, **Andresen BS**, Rosenberg T (2019) A pathogenic haplotype, common in Europeans, causes autosomal recessive albinism and accounts for missing molecular genetic explanation of OCA1. *Scientific Reports* 9:645
133. Schaefer S, Doktor TK, Frederiksen S, Chea K, Hlavacova M, Bruun GH, Rabjerg M, **Andresen BS**, Dominguez I, Guerra B (2019) Down-regulation of CK2 $\alpha$  correlates with decreased expression levels of DNA replication minichromosome maintenance protein complex (MCM) genes. *Scientific Reports* 9(1):14581.
134. Grønning AGB, Doktor TK, Larsen SJ, Petersen USS, Holm LL, Bruun GH, Hansen MB, Hartung AM, Baumbach J, **Andresen BS** (2020) DeepCLIP: predicting the effect of mutations on protein-RNA binding with deep learning. *Nucleic Acids Research* 48:7099-7118.
135. Lund A, Wibrand F, Skogstrand K, Cohen A, Christensen M, Jäpelt RB, Dunø M, Skovby F, Nørgaard-Pedersen B, Gregersen N, **Andresen BS**, Olsen RKJ, Hougaard D (2020) Danish expanded newborn screening is a successful preventive public health programme. *Dan Med J*. 67(1). pii: A06190341.
136. Guerra B, Dembic M, Siddiqui MA, Dominguez I, Ceppi P, **Andresen BS** (2020) Lack of CK2 $\alpha$  leads to up-regulation of the cyclin-dependent kinase inhibitor p27KIP1 in myoblasts as an indicator of unfavorable conditions for cell growth. *Cellular Physiology and Biochemistry* 54:1177-1198.
137. Frederiksen SB, Holm LL, Larsen MR, Doktor TK, Andersen HS, Hua Y, Hastings ML, Krainer AR, **Andresen BS** (2021) Identification of SRSF10 as a novel regulator of *SMN* ISSN1. *Human Mutation* 42:246-260. (Selected as “Editor’s Choice”).
138. Lund A, Wibrand F, Skogstrand K, Bækvad-Hansen M, Gregersen N, **Andresen BS**, Hougaard D, Dunø M, Olsen RKJ (2021) Use of molecular genetic analyses in Danish routine newborn screening. *Int J Neonatal Screen* 7:50.
139. Petersen USS, Doktor TK and **Andresen BS** (2022) Pseudoexon activation in disease by non-splice site deep intronic sequence variation – wildtype pseudoexons constitute high-risk sites in the human genome. *Human Mutation* 43: 103-127.
140. Holm LL, Doktor TK, Hansen MB, Petersen USS and **Andresen BS** (2022) *ACADM* exon 5 is a vulnerable exon highly dependent on a balance between splicing enhancers and silencers. *Human Mutation* 43:253–265. (Selected as

“Editor’s Choice”).

141. Alsing S, Doktor TK, Askou AL, Jensen AG, Ahmadov U, Kristensen LS, **Andresen BS** Aagaard, Corydon TJ (2022) VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy. *Molecular Therapy - Nucleic Acids*. 28:58–76.
142. Guerra B, Doktor TK, Frederiksen SB, Somyajit K, **Andresen BS** (2022) Essential role of CK2a for the interaction and stability of replication fork factors during DNA synthesis and activation of S-phase checkpoint. *Cellular and Molecular Life Sciences* **79** (6):339.
143. Geertsen Keller J, Mejlstrup Hymøller K, Eriksen MT, Hansen NY, Erlandsen JU, Tesauro C, Simonsen AK, Andersen AB, Petersen KV, Holm LL, Stougaard M, **Andresen BS**, Kristensen P, Haugaard R, Knudsen BR (2022) Topoisomerase 1 Inhibits MYC Promoter Activity by Inducing G-Quadruplex Formation. *Nucleic Acids Research* 50:6332–42.
144. Martínez-Pizarro A, Leal F, Holm LL, Doktor TK, Petersen USS, Bueno M, Thöny B, Pérez B, **Andresen BS**, Desviat LR (2022) Antisense oligonucleotide rescue of deep-intronic variants activating pseudoexons in the PTS gene. *Nucleic Acid Therapeutics* 32:378–390.
145. Thomassen M, Mesman RLS, Hansen TVO, Menendez M, Rossing M, Esteban-Sánchez A, Tudini E, Törngren T, Parsons MT, Pedersen IS, Teo SH, Kruse TA, Møller P, Borg Å, Jensen UB, Christensen LL, Singer CF, Muhr D, Santamarina M, Brandao R, **Andresen BS**, Feng BJ, Canson D, Richardson ME, Karam R, Pesaran T, LaDuca H, Conner BR, Abualkheir N, Hoang L, Calléja FMGR, Andrews L, James PA, Bunyan D, Hamblett A, Radice P, Goldgar DE, Walker LC, Engel C, Claes KBM, Machácková E, Baralle D, Viel A, Wappenschmidt B, Lazaro C, Vega A, Consortium E, Vreeswijk MPG, de la Hoya M, Spurdle AB on behalf of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) (2022) Clinical, splicing and functional analysis to classify BRCA2 exon 3 variants: application of a points-based ACMG-AMP approach. *Human Mutation* 43:1921–1944.
146. Vazari A, Deyneko IV, Bruun GH, Dembic M, Hofmann W, Cebotari VM, Ginda SS, **Andresen BS**, Illig T (2022) Candidate genes and sequence variants for susceptibility to mycobacterial infection identified by whole-exome sequencing. *Front. Genet.* 13:969895.
147. Larsen TV, Maansson CT, Daugaard TF, **Andresen BS**, Sørensen BS, Nielsen AL (2023) Trans-regulation of alternative PD-L1 mRNA processing by CDK12 in non-small-cell lung cancer cells. *Cells* 12(24), 2844.
148. Petersen USS, Dembic M, Martínez-Pizarro A, Holm LL, Richard E, Havelund JF, Doktor TK, Larsen MR, Færgeman NJK, Desviat LR and **Andresen BS** (2024) Regulating *PCCA* gene expression by modulation of pseudoexon splicing patterns to rescue enzyme activity in propionic acidemia. *Molecular Therapy - Nucleic Acids* 35(1):102101.
149. Terkelsen T, Mikkelsen NS, Bak EN, Vad-Nielsen J, Blechingberg J, Weiss S, Drue SO, Andersen H, **Andresen BS**, Bak RO, Jensen UB (2024) CRISPR activation to characterize splice-altering variants in easily accessible cells. *American Journal of Human Genetics* 111:309-322.
150. Holm LL, Doktor TK, Flugt KK, Petersen USS, Petersen R and **Andresen BS** (2024) All exons are not created equal - Exon vulnerability determines the effect of exonic mutations on splicing. *Nucleic Acids Research* 52:4588-4603.
151. Martínez-Pizarro A, Álvarez M, Dembic M, Lindegaard CA, Castro M, **Andresen BS**, Desviat LR (2024) Splice-switching antisense oligonucleotides correct PAH exon 11 skipping defects and rescue enzyme activity in phenylketonuria. *Nucleic Acid Therapeutics* 34(3):134-142.
152. Guerra B, Jurcic K, Van der Poel R, Cousineau SL, Doktor TK, Lindegaard CA, Buchwald LM, Roffey S, Lindegaard CA, Ferrer AZ, Siddiqui MA, Gyenis L, **Andresen BS**, Litchfield DW (2024) Protein kinase CK2 sustains de novo fatty acid synthesis by regulating the expression of SCD1 in human renal cancer cells. *Cancer Cell International* 24(1):432.
153. Buchwald LM, Neess D, Hansen D, Doktor TK, Ramesh V, Steffensen LB, Blagoev B, Litchfield DW, **Andresen BS**, Ravnskjaer K, Færgeman NJ, Guerra B (2025) Body weight control via protein kinase CK2: diet-induced obesity counteracted by pharmacological targeting. *Metabolism - Clinical and Experimental*. 162:156060.
154. Martínez-Pizarro A, Pico S, Álvarez M, Pose-Utrilla J, Holm LL, Doktor TK, **Andresen BS**, Lucas JJ, Desviat LR (2025) Oligonucleotides targeting the 3' splice site downstream of a microexon as an innovative therapy for autism. *Nucleic Acids Research – Molecular Medicine* Vol 2, Issue 4, ugaf035, <https://doi.org/10.1093/narmme/ugaf035>
155. Farooq M, Bruun GH, Sarusie MVK, Kessel L, Akhtar H, Abdullah U, Anjum I, Doktor TK, **Andresen BS**, Baig SM, Larsen LA, Grønsvov K (2025) Oculocutaneous albinism variants in 28 consanguineous families and functional classification of a pathogenic deep intron variant in TYR. (*Medrxiv* :<https://www.medrxiv.org/content/10.1101/2025.02.20.25322192v1> and submitted to *European J Human Genetics*).
156. Bang JV, .. Valcárcel J, Sattler M, **Andresen BS** (2025) Genotype-Phenotype Correlation in RBM10-Associated Syndromes. *MedRxiv*. <https://doi.org/10.1101/2025.08.05.25330579> and submitted to *Am J Hum Genet*).
157. Nørreremark MF, Petersen R, Ruppert PMM, Jul ES, Doktor TK, Nielsen R, Kappel JF, Larsen S, Kornfeld JW, Mandrup S, **Andresen BS**, Havelund J, Neess D and Færgeman NJ (2025) Acyl-CoA Binding Protein in White and Brown Adipose Tissue is Dispensable for Systemic Energy Metabolism in Mice. *Acta Physiologica*(Submitted).
158. Urbanska EM, Doktor TK, Melchior LC, Petersson ES, Sørensen JB, Santoni-Rugiu E, **Andresen BS**, Grauslund M (2025) Improvement of diagnostics in NSCLC patients with MET exon 14 mutations using complementary DNA/RNA-NGS and identification of two novel exonic splicing mutations. *International Journal of Molecular Sciences* (Submitted).

#### Not peer reviewed

1. Vockley J, Longo N, **Andresen BS**, Bennett MJ (2017) Fatty-acid oxidation defects. Chapter 9: *Pediatric Endocrinology and Inborn errors of Metabolism*. Edited by Sarafoglou K. McGraw-Hill. 2<sup>nd</sup> edition. p125-144. ISBN-13: 978-0071773133.
2. \* **Patent**: “RAS Exon 2 skipping for cancer treatment” – US10.266.828 (Granted 23/4-2019) and PCT/EP2014/078029. Published: WO 2015/091525. Inventor: Brage Storstein Andresen, SDU.

3. **Andresen BS** (2012) Reading through nonsense as therapy for Propionic Acidemia? (Article in brief) - *Human Mutation* - 33(6):v.doi:10.1002/humu.22575. PMID: 22570303.
4. Strauss AW, **Andresen BS**, Bennett MJ (2009) Chapter 5: Fatty-acid oxidation defects. pp. 51-70. In: *Pediatric Endocrinology and Inborn errors of Metabolism*. Edited by Sarafoglou K. McGraw-Hill. ISBN: 0071439153/9780071439152.
5. **Andresen BS** (2009) Very-long-chain Acyl-CoA dehydrogenase deficiency (VLCADD). Invited review for *Encyclopedia of Molecular Mechanisms of Disease*. Springer Verlag. Edited by Florian Lang, (ISBN 978-3-540-29676-8 / 978-3-540-33445-3 (Print/Online). Part 22. Pages 2202-04. <http://www.springerreference.com/docs/html/chapterdbid/110169.html>
6. **Andresen BS** and Krainer AR (2009) When the genetic code is not enough – How sequence variations can affect pre-mRNA splicing and cause (complex) disease. Chapter 15 (pp.165-182) in *Genetics of Complex Human Diseases*. Edited by Laura Almasy and Ammar Al-Chalabi. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. Paperback: ISBN 978-087969883-6 / Hardcover: ISBN 978-087969882-9).
7. Rapport fra arbejdsgruppe nedsat af sundhedsstyrelsen (December 2008) - *Biokemisk screening for medfødt sygdom hos nyfødte* – Medforfatter til rapporten, der blev til efter 2 års arbejde i en ekspertgruppe udpeget af sundhedsstyrelsen. Eneforfatter af afsnittet omkring molekylær genetik. Rapporten har bla. dannet basis for beslutningen om pr. 2 februar 2009 at indføre rutinemæssig MS-MS baseret nyfødtsscreening af hæleprøver for en stor gruppe af medfødte stofskiftesygdomme i Danmark.
8. Bross P, **Andresen BS**, Corydon TJ, Gregersen N (2004) Protein misfolding and degradation in genetic diseases. In: *Encyclopedia of the Human genome (Cooper, D.N.,ed)* pp.97-121. Nature Publishing Group.
9. Abdel-Razik NE, Nguyen TV, **Andresen BS**, Mohsen AW, Vockley J, Ghisla S (2002) Purification and Partial Characterization of Human Isobutyryl-CoA Dehydrogenase: A Novel Member of the Acyl-CoA Dehydrogenases Family. In: Flavins and flavoproteins. 2002: Proceedings of the fourteenth international symposium, St. John's College, University of Cambridge, UK, July 14 - 18, 2002, pp. 831-835.
10. Bross P, **Andresen BS** and Gregersen N (1998) Impaired folding and subunit assembly as disease mechanism: The example of medium-chain acyl-CoA dehydrogenase deficiency. In Cohn WE, Moldave K (eds). *Progress in nucleic acids research and molecular biology*. Academic Press. San Diego, CA, USA Volume 58: pp301-337.
11. **Andresen BS** (1996) Molecular diagnosis and characterization of medium-chain acyl-coA dehydrogenase deficiency. *Ph.D.-thesis*, Faculty of Health sciences, Aarhus University (Defended Feb. 28 1996). Abstract in *Ugeskrift for Læger* (1996; **158**:1686-1687) and *Danish Medical Bulletin* **43**:367-368.
12. Marfá MP, Busca MAV, Rubio AR, Godino PB, Gregersen N, **Andresen BS**, Alvarez yEF (1994) Diagnóstico y tratamiento de una paciente con deficiencia de acil-coenzima a deshidrogenasa de cadena media (mutación G985). *Rev Esp Pediatr*. 50: 23-27.
13. Gregersen N, **Andresen BS**, Bross P, Bolund L and Kølvråa S. (1994) Disorders of mitochondrial fatty acid oxidation - especially medium-chain acyl-coA dehydrogenase (MCAD) deficiency. Farriaux JP and Dhondt JL (eds.) *New horizons in neonatal screening*, Elsevier, Amsterdam, 247-255.
14. **Andresen BS**, Bross P, Jensen TG, Knudsen I, Winter V, Kølvråa S, Bolund L, Gregersen N (1995) Molecular diagnosis and characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. *Scand J Clin Lab Invest Suppl 2*, p9-26. Special issue with the five finalists from "Astrup Prize competition 1994".
15. Bross P, Jensen T, Kräutle F, Winter V, **Andresen BS**, Engst S, Bolund L, Kølvråa S, Ghisla S, Rasched I and Gregersen N (1992) Characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency with a point mutation associated with MCAD deficiency. In: Tanaka K., Coates P. (eds.), *New developments in fatty acid oxidation*, Wiley-Liss, New York. pp473-478.
16. Gregersen N, Winter V, Kølvråa S, **Andresen BS**, Bross P, Blakemore AIF, Curtis D and Bolund L. (1992) Molecular analysis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: A diagnostic approach. In: Tanaka K., Coates P. (eds.) *New developments in fatty acid oxidation*, Wiley-Liss, New York. pp441-452.
17. Bross P, Kräutle F, Stiemke J, Ghisla S, Rasched I, Gregersen N, **Andresen BS**, Strauss A and Kelly D. (1990). Biochemical characterisation of mutant human medium-chain acyl-CoA dehydrogenase present in patients having deficient activity. In *Flavin and Flavoprotein; Proceedings of the 10 th. International Symposium*; (Curti B, Ronchi S and Zanetti G (eds)) W.DeGruyter, Berlin; 895-900.

## Software and Database submission

1. *DeepClip* - <https://deepclip-web.compbio.sdu.dk>

2. *VulExMap* - <https://vulxmap.compbio.sdu.dk>

- A. Doktor TK, Hua Y, Andersen HS, Brøner S, Krainer AR, **Andresen BS** (2015) RNA-seq data from SMA mice. ArrayExpress Archive: <http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3664/>
- B. Bruun GH, Doktor TK, Masuda A, Krainer AR, Ohno K, **Andresen BS** (2015) iCLIP data from hnRNP A1 iCLIP project. ArrayExpress Archive: <http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3612/>
- C. Doktor TK, Schroeder LD, Andersen HS, Broener S, Soerensen CB, **Andresen BS** (2014) Pig SMN1 gene from Yucatan strain. GenBank/EMBL accession no. KF585502.
- D. Masuda A, Andersen HS, Doktor TK, Okamoto T, Ito M, **Andresen BS**, Ohno K (2012). RNA CLIP-seq for Cugbp1, Mbnl1 and Ptpbp1 in mouse C2C12 myoblasts. Source: ArrayExpress Archive: <http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-414/>

- E. Andresen BS** (2000) Homo sapiens short/branched chain acyl-CoA dehydrogenase (ACADSB) gene. GenBank/EMBL accession no's. AF260678-AF260668.
- F. Corydon TJ, Wilsbech M, Jespersgaard C, Andresen BS, Borglum AD, Pedersen S, Bolund L, Gregersen N and Bross P.** (2000) Homo sapiens mRNA for ClpX-like protein. GenBank/EMBL accession no. AJ006267.
- G. Corydon TJ, Wilsbech M, Jespersgaard C, Andresen BS, Borglum AD, Pedersen S, Bolund L, Gregersen N and Bross P.** (2000) Mus musculus partial mRNA for CLPX. GenBank/EMBL accession no's. AJ276991.
- H. Corydon TJ, Wilsbech M, Jespersgaard C, Andresen BS, Borglum AD, Pedersen S, Bolund L, Gregersen N and Bross P.** (2000) Homo sapiens partial CLPX gene, exon 1 and joined cds (exons 1-14) AJ276980.
- I. Andresen BS** (2000) Homo sapiens acyl-CoA dehydrogenase 8 (*ACAD8*) gene. GenBank/EMBL accession no's. AF260679-AF260689.
- J. Andresen BS** (1999) M. musculus partial ClpP protease gene promoter region, strain C57BL/6J. GenBank/EMBL accession no. AJ238605
- K. Andresen BS** (1999) Mus musculus partial ClpP protease gene promoter region, strain, Spretus. GenBank/EMBL accession no. AJ238606.
- L. Andresen BS** (1998) M. musculus VLCAD gene partial promoter. EMBL Nucleotide Sequence Database, Accession number AJ012054.
- M. Andresen BS** (1998) H Sapiens VLCAD gene partial promoter. EMBL Nucleotide Sequence Database, Accession number AJ012053.
- N. Andresen BS** (1998) M. musculus mRNA for ClpP protease. EMBL Nucleotide Sequence Database, Accession number AJ005253.
- O. Andresen BS** (1998) M. musculus ClpP protease gene. EMBL Nucleotide Sequence Database. Acc. No. AJ012249 to AJ012253.
- P. Andresen BS** (1997) M. musculus VLCAD gene. EMBL Nucleotide Sequence Database, Accession number Y11770.
- Q. Andresen BS** (1996) Mouse BALB/c VLCAD gene. EMBL Nucleotide Sequence Database, Accession number Z7118.
- R. Andresen BS** (1995) H. Sapiens HVLCAD gene. EMBL Nucleotide Sequence Database, Accession number X86556.
- <!-- /\* Style Definitions \*/ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} h1 {mso-style-priority:9; mso-style-unhide:no; mso-style-qformat:yes; mso-style-link:"Overskrift 1 Tegn"; mso-style-next:Normal; margin-top:24.0pt; margin-right:0cm; margin-bottom:0cm; margin-left:0cm; line-height:115%; mso-pagination:widow-orphan lines-together; page-break-after:avoid; mso-outline-level:1; font-size:14.0pt; font-family:"Cambria",serif; mso-ascii-font-family:Cambria; mso-ascii-theme-font:major-latin; mso-fareast-font-family:"MS Gothic"; mso-fareast-theme-font:major-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:major-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:major-bidi; color:#365F91; mso-themecolor:accent1; mso-themeshade:191; mso-font-kerining:0pt; mso-fareast-language:EN-US; font-weight:bold;} h3 {mso-style-noshow:yes; mso-style-priority:9; mso-style-qformat:yes; mso-style-link:"Overskrift 3 Tegn"; mso-style-next:Normal; margin-top:2.0pt; margin-right:0cm; margin-bottom:0cm; margin-left:0cm; mso-pagination:widow-orphan lines-together; page-break-after:avoid; mso-outline-level:3; font-size:12.0pt; font-family:"Cambria",serif; mso-ascii-font-family:Cambria; mso-ascii-theme-font:major-latin; mso-fareast-font-family:"MS Gothic"; mso-fareast-theme-font:major-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:major-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:major-bidi; color:#243F60; mso-themecolor:accent1; mso-themeshade:127; font-weight:normal;} h4 {mso-style-noshow:yes; mso-style-priority:9; mso-style-qformat:yes; mso-style-link:"Overskrift 4 Tegn"; mso-style-next:Normal; margin-top:10.0pt; margin-right:0cm; margin-bottom:0cm; margin-left:0cm; line-height:115%; mso-pagination:widow-orphan lines-together; page-break-after:avoid; mso-outline-level:4; font-size:11.0pt; font-family:"Cambria",serif; mso-ascii-font-family:Cambria; mso-ascii-theme-font:major-latin; mso-fareast-font-family:"MS Gothic"; mso-fareast-theme-font:major-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:major-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:major-bidi; color:#4F81BD; mso-themecolor:accent1; mso-fareast-language:EN-US; font-weight:bold; font-style:italic;} p.MsoCommentText, li.MsoCommentText, div.MsoCommentText {mso-style-noshow:yes; mso-style-priority:99; mso-style-link:"Kommentartekst Tegn"; margin-top:0cm; margin-right:0cm; margin-bottom:8.0pt; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:ES; mso-fareast-language:EN-US;} p.MsoHeader, li.MsoHeader, div.MsoHeader {mso-style-priority:99; mso-style-link:"Sidehoved Tegn"; margin:0cm; mso-pagination:widow-orphan; tab-stops:center 240.95pt right 481.9pt; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;} p.MsoFooter, li.MsoFooter, div.MsoFooter {mso-style-priority:99; mso-style-link:"Sidefod Tegn"; margin:0cm; mso-pagination:widow-orphan; tab-stops:center 240.95pt right 481.9pt; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-fareast-language:EN-US;} span.MsoCommentReference {mso-style-noshow:yes; mso-style-priority:99; mso-ansi-font-size:9.0pt; mso-bidi-font-size:9.0pt;} p.MsoListBullet, li.MsoListBullet, div.MsoListBullet {mso-style-priority:36; mso-style-qformat:yes; margin:0cm; mso-add-space:auto; text-indent:0cm; line-height:115%; mso-pagination:widow-orphan; mso-list:l0 level1 lfo8; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"MS Mincho"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-



family:"Cambria",serif; mso-ascii-font-family:Cambria; mso-ascii-theme-font:major-latin; mso-fareast-font-family:"MS Gothic"; mso-fareast-theme-font:major-fareast; mso-hansi-font-family:Cambria; mso-hansi-theme-font:major-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:major-bidi; color:#4F81BD; mso-themecolor:accent1; font-weight:bold; font-style:italic;} span.AlmindeligtekstTegn {mso-style-name:"Almindelig tekst Tegn"; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:"Almindelig tekst"; mso-bidi-font-size:10.5pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-hansi-font-family:Calibri;} span.apple-converted-space {mso-style-name:apple-converted-space; mso-style-unhide:no;} span.SidehovedTegn {mso-style-name:"Sidehoved Tegn"; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:Sidehoved;} span.SidefodTegn {mso-style-name:"Sidefod Tegn"; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:Sidefod;} span.MarkeringsbobletekstTegn {mso-style-name:"Markeringsbobletekst Tegn"; mso-style-noshow:yes; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:Markeringsbobletekst; mso-ansi-font-size:8.0pt; mso-bidi-font-size:8.0pt; font-family:"Tahoma",sans-serif; mso-ascii-font-family:Tahoma; mso-hansi-font-family:Tahoma; mso-bidi-font-family:Tahoma;} span.jrnl {mso-style-name:jrnl; mso-style-unhide:no;} p.Titel1, li.Titel1, div.Titel1 {mso-style-name:Titel1; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} p.desc, li.desc, div.desc {mso-style-name:desc; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} p.details, li.details, div.details {mso-style-name:details; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} p.Titel2, li.Titel2, div.Titel2 {mso-style-name:Titel2; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} span.cit-ahead-of-print-date {mso-style-name:cit-ahead-of-print-date; mso-style-unhide:no;} span.cit-sep {mso-style-name:cit-sep; mso-style-unhide:no;} span.cit-doi {mso-style-name:cit-doi; mso-style-unhide:no;} p.Titel3, li.Titel3, div.Titel3 {mso-style-name:Titel3; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} p.Titel4, li.Titel4, div.Titel4 {mso-style-name:Titel4; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";} span.BrødttekstTegn {mso-style-name:"Brødttekst Tegn"; mso-style-noshow:yes; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:Brødttekst; mso-ansi-font-size:14.0pt; mso-bidi-font-size:14.0pt; font-family:"Times New Roman",serif; mso-ascii-font-family:"Times New Roman"; mso-fareast-font-family:"Times New Roman"; mso-hansi-font-family:"Times New Roman"; mso-bidi-font-family:"Times New Roman"; mso-ansi-language:EN-AU; mso-fareast-language:DA; mso-bidi-language:HE; font-weight:bold;} span.field {mso-style-name:field; mso-style-unhide:no;} span.a-size-base {mso-style-name:a-size-base; mso-style-unhide:no;} span.cit-print-date {mso-style-name:cit-print-date; mso-style-unhide:no;} span.cit-vol {mso-style-name:cit-vol; mso-style-unhide:no;} span.cit-issue {mso-style-name:cit-issue; mso-style-unhide:no;} span.cit-pages {mso-style-name:cit-pages; mso-style-unhide:no;} span.cit-first-page {mso-style-name:cit-first-page; mso-style-unhide:no;} span.cit-last-page {mso-style-name:cit-last-page; mso-style-unhide:no;} span.KommentartekstTegn {mso-style-name:"Kommentartekst Tegn"; mso-style-noshow:yes; mso-style-priority:99; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:Kommentartekst; mso-ansi-font-size:12.0pt; mso-bidi-font-size:12.0pt; mso-ansi-language:ES;} span.size-m {mso-style-name:size-m; mso-style-unhide:no;} p.article-type, li.article-type, div.article-type {mso-style-name:article-type; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:10.0pt; font-family:Times; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} span.journal-title {mso-style-name:journal-title; mso-style-unhide:no;} span.divider {mso-style-name:divider; mso-style-unhide:no;} span.vcard {mso-style-name:vcard; mso-style-unhide:no;} span.fn {mso-style-name:fn; mso-style-unhide:no;} span.comma {mso-style-name:comma; mso-style-unhide:no;} span.item {mso-style-name:item; mso-style-unhide:no;} p.volume-issue, li.volume-issue, div.volume-issue {mso-style-name:volume-issue; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:10.0pt; font-family:Times; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} span.val {mso-style-name:val; mso-style-unhide:no;} p.page-range, li.page-range, div.page-range {mso-style-name:page-range; mso-style-unhide:no; mso-margin-top-alt:auto; margin-right:0cm; mso-margin-bottom-alt:auto; margin-left:0cm; mso-pagination:widow-orphan; font-size:10.0pt; font-family:Times; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} span.highlight {mso-style-name:highlight; mso-style-unhide:no;} span.docsum-journal-citation {mso-style-name:docsum-journal-citation; mso-style-unhide:no;} span.highwire-cite-metadata-journal {mso-style-name:highwire-cite-metadata-journal; mso-style-unhide:no;} span.highwire-cite-metadata-pages {mso-style-name:highwire-cite-metadata-pages; mso-style-unhide:no;} span.highwire-cite-metadata-doi {mso-style-name:highwire-cite-metadata-doi; mso-style-unhide:no;} span.doilabel {mso-style-name:doi\_label; mso-style-unhide:no;} p.Default, li.Default, div.Default {mso-style-name:Default; mso-style-unhide:no; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; mso-layout-grid-align:none; text-autospace:none; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; color:black; mso-fareast-language:EN-US;} span.typography-modulelvnit {mso-style-name:typography-modulelvnit; mso-style-unhide:no;} span.citation-part {mso-style-name:citation-part; mso-style-unhide:no;} span.docsum-pmid {mso-style-name:docsum-pmid; mso-style-unhide:no;} span.wixui-rich-text\_\_text {mso-style-name:wixui-rich-text\_\_text; mso-style-unhide:no;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:11.0pt; mso-ansi-font-size:11.0pt; mso-bidi-font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-

family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:0pt; mso-ligatures:none; mso-fareast-language:EN-US; . . . . .





font-weight:bold;} @list l19 {mso-list-id:1832286524; mso-list-type:hybrid; mso-list-template-ids:1081653344 -156753102 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;} @list l19:level1 {mso-level-tab-stop:36.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-language:DA;} @list l19:level2 {mso-level-number-format:alpha-lower; mso-level-tab-stop:72.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l19:level3 {mso-level-number-format:roman-lower; mso-level-tab-stop:108.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l19:level4 {mso-level-tab-stop:144.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l19:level5 {mso-level-number-format:alpha-lower; mso-level-tab-stop:180.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l19:level6 {mso-level-number-format:roman-lower; mso-level-tab-stop:216.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l19:level7 {mso-level-tab-stop:252.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l19:level8 {mso-level-number-format:alpha-lower; mso-level-tab-stop:288.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l19:level9 {mso-level-number-format:roman-lower; mso-level-tab-stop:324.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l20 {mso-list-id:2022195720; mso-list-type:hybrid; mso-list-template-ids:-1960399332 -156753102 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;} @list l20:level1 {mso-level-tab-stop:36.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-language:DA;} @list l20:level2 {mso-level-number-format:alpha-lower; mso-level-tab-stop:72.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l20:level3 {mso-level-number-format:roman-lower; mso-level-tab-stop:108.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l20:level4 {mso-level-tab-stop:144.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l20:level5 {mso-level-number-format:alpha-lower; mso-level-tab-stop:180.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l20:level6 {mso-level-number-format:roman-lower; mso-level-tab-stop:216.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l20:level7 {mso-level-tab-stop:252.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l20:level8 {mso-level-number-format:alpha-lower; mso-level-tab-stop:288.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l20:level9 {mso-level-number-format:roman-lower; mso-level-tab-stop:324.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l21 {mso-list-id:2024815758; mso-list-type:hybrid; mso-list-template-ids:-168009962 1027535570 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;} @list l21:level1 {mso-level-tab-stop:36.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-language:DA; mso-ansi-font-style:normal; mso-bidi-font-style:normal;} @list l21:level2 {mso-level-number-format:alpha-lower; mso-level-tab-stop:72.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l21:level3 {mso-level-number-format:roman-lower; mso-level-tab-stop:108.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l21:level4 {mso-level-tab-stop:144.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l21:level5 {mso-level-number-format:alpha-lower; mso-level-tab-stop:180.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l21:level6 {mso-level-number-format:roman-lower; mso-level-tab-stop:216.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l21:level7 {mso-level-tab-stop:252.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l21:level8 {mso-level-number-format:alpha-lower; mso-level-tab-stop:288.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l21:level9 {mso-level-number-format:roman-lower; mso-level-tab-stop:324.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l22 {mso-list-id:2042513499; mso-list-type:hybrid; mso-list-template-ids:1272979818 -1 -1 -1 -1 -1 -1 -1 -1 -1;} @list l22:level1 {mso-level-tab-stop:36.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-language:DA;} @list l22:level2 {mso-level-number-format:alpha-lower; mso-level-tab-stop:72.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l22:level3 {mso-level-number-format:roman-lower; mso-level-tab-stop:108.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l22:level4 {mso-level-tab-stop:144.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l22:level5 {mso-level-number-format:alpha-lower; mso-level-tab-stop:180.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l22:level6 {mso-level-number-format:roman-lower; mso-level-tab-stop:216.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l22:level7 {mso-level-tab-stop:252.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l22:level8 {mso-level-number-format:alpha-lower; mso-level-tab-stop:288.0pt; mso-level-number-position:left; text-indent:-18.0pt;} @list l22:level9 {mso-level-number-format:roman-lower; mso-level-tab-stop:324.0pt; mso-level-number-position:right; text-indent:-9.0pt;} @list l23 {mso-list-id:2118988446; mso-list-template-ids:1150870676;} @list l23:level1 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:36.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Symbol;} @list l23:level2 {mso-level-number-format:bullet; mso-level-text:o; mso-level-tab-stop:72.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:"Courier New"; mso-bidi-font-family:"Times New Roman";} @list l23:level3 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:108.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l23:level4 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:144.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l23:level5 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:180.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l23:level6 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:216.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l23:level7 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:252.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l23:level8 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:288.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l23:level9 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:324.0pt; mso-level-number-position:left; text-indent:-18.0pt; mso-ansi-font-size:10.0pt; font-family:Wingdings;} -->

S. Bross P, **Andresen BS**, Knudsen I, Kruse TA, Gregersen N (1995) Human ClpP protease, cDNA sequence EMBL Nucleotide Sequence Database, Accession number Z50853.

## Teaching Portfolio

Brage Storstein Andresen  
Institut for Biokemi og Molekylær Biologi  
Translational Biologi  
E-mail: bragea@bmb.sdu.dk  
Telefon: +4565502413



## 1. Formel pædagogisk uddannelse

- 1996 Educational course for assistant professors, Sandbjerg gods, AU.

## 2. Uddannelsesadministrative opgaver

- Head of teaching, Dept. Human Genetics, AU (2007-2008).
- Educational board, BMB, SDU (2009-present).
- Head of teaching, BMB, SDU (2015-present).
- Studienævnrepræsentant for BMB, NAT, SDU.
- Medlem af uddannelsesudvalget, NAT, SDU.
- Viceinstituttleder og ansvarlig for uddannelserne i Biomedicin og BMB.
- Member of the Executive board: Nordic Network Biomedicine, Nordplus/ERASMUS+, OERCompBiomed (2017-)

## 3. Erfaring med undervisning, vejledning og eksamen

- Teaching in Medical Genetics for Medical Students and Students in Odontology, Faculty of Health, AU for more than 10 years from 1995-2008. Lectures, examinatoriums and lab course. Together with Ass. Professor Thomas Corydon, I developed and was the responsible teacher for the 3 day laboratory course in Medical genetics at Faculty of Health, AU. This course had >200 participants every half year. •In 2008 I developed and designed the new course in Medical Genetics for the new study in Molecular Medicine together with 3 other associate professors at AU. I left AU for my position at SDU, when the course started, but it has been running successfully since then. I am now external censor for this course. •I have for more than 15 years been developing and teaching at annual courses (Lab and lectures) in for Molecular Medicine for Medical Science Technologists (Hospitalslaboranter - Dbio). •I have been teaching and co-designing a 4 day Ph.D. course, at AU in Molecular Medicine (Lab exercises and lectures) for more than 15 years until my assignment in 2008 at SDU. •I have for the last 14 years (2008-2020) given 2-3 annual lectures at Ph.D. courses at AU ("From gene to function", "Molecular Medicine" and "Molecular Genetics in Endocrinology and Cardiology – Translational Medicine"). •I have given numerous lectures at the A-courses in clinical genetics, which is part of the specialty education for MD's in Clinical Genetics. •I was for 5 years (2009-2013) the responsible teacher for the course in advanced Molecular Biology (BMB508) and BMB809 – 10ECTS (Lectures, Examinatoriums and 3 day lab course). I shared the lectures with Professor Jens Andersen, BMB and carried out the 3 day lab course together with members from my own research group.
- Together with Associate Professor Finn Kirpekar I developed "Elitemodulet i Molecular Diagnostics (BMB814 - 25 ECTS – 1 year). This was an interdisciplinary course between Faculty of Health and Faculty of Science, SDU employing teachers from both faculties. I developed and gave >½ the lectures in the module in Medical Genetics (20 Lectures, 18 Examinatoriums and 4 day lab course). This course turned out to be too hard to coordinate, so after 2 years we decided not to offer it anymore. •I developed the course, Human Molecular Medical Genetics – Diagnostics and Pathology (BMB815) – 5 ECTS and this has now been running successfully since 2011 and is again offered in the autumn of 2020.
- In the four years, 2010-2014, autumn, I shared the lectures in molecular biology for medical students (Modul 2) with another Professor at BMB. •I have in 2013 developed and has since been the responsible teacher at the 5 ECTS bachelor course "Human diseases" BMB531 for students in biochemistry and molecular biology (BMB) and students in biomedicine at SDU. This course is attended by approx. 200 students. I share the lectures in this course with Professor, Stephen Douthwaite, BMB and Associate Professor Barbara Guerra, BMB. •Since autumn 2014 I have given 4 lectures/year in the course BMB822, "Modern trends and technologies in molecular cell biology". •In the period up until 2008 I was censoring the written exams from the BMB508 course and before then the course in Genetics from, BMB, SDU. •Since 1991 I have supervised >50 master thesis students (8 last year – 8 this year), numerous bachelor students, ISA and ERASMUS students, who have performed their projects in my laboratory. Additionally I have also been supervisor on several students performing their projects outside my lab. •I have supervised 2 Ph.D. students in Medicine at AU. At SDU I have supervised four Ph.D. students in Molecular Biology who finished in December 2013, May 2015, Oct. 2018 and February 2020. I am currently supervising 3 Ph.D. students in Molecular Biology. •I have supervised one candidate in the pedagogical course for assistant professors at SDU in the Autumn of 2012. •For the past 12 years (2008-2020) I have been censoring Medical Genetics written exam for Medical Students from Faculty of Biomedicine, AU. •I have also censured the written exam in Medical Genetics for Students in Molecular Medicine Students from Faculty of Biomedicine, AU for the last >10 years. •I have for several years censured the written exams in Medical Genetics for medical students at Faculty of Health, KU. •For 13 years (2008-2020) I have censured the written reports from the course in Applied Molecular Biology, Faculty of Science, AU. •I have censured numerous bachelor- and master- of science thesis, gold medal- (KU) or diploma- (AU)

assignments etc. from the Faculties of Health and Faculties of Science from AU and KU. •I have been external evaluator of numerous Ph.D. dissertations from AU, SDU and KU, as well as from other countries.

#### **4. Metoder, materialer og redskaber**

- As can be seen from the above I have extensive experience with teaching in many contexts spanning from 1 day- 1 week- courses for medical laboratory technologist to MD's taking their specialty education or Ph.D. courses. I have lectured for big audiences >200 students at the master- bachelor- level in Medicine, Odontology, Biochemistry and Molecular Biology and I also have extensive experience with teaching in smaller audiences of 10-30 people. I also have extensive experience with development, planning and teaching at hands-on lab courses for different types of students.
- Depending on the size of the audience I use a mixture of PowerPoint presentation and writing on blackboard/white board.
- I have written several lab course manuals for the various lab courses. •I attempt to include questions and small activities during my lectures in order to keep the students focused. •In recent years I have been involved in developing online courses.

#### **5. Uddannelsesudvikling og universitetspædagogisk forskning**

- I participated in the "Future Search" process in the spring of 2011 aiming at overall improvements of the educations at Faculty of Science, SDU.
- In the autumn of 2012 I was a member of the task-force at the Faculty of Science, SDU, who should redesign the common 1 year in Science for all students.
- As chair of the teaching committee and Deputy Head of Department at BMB I am constantly involved in developing and redesigning courses and the overall planning of our educations.

#### **6. Refleksion over egen pædagogisk praksis og fremtidig udvikling, herunder undervisningsevalueringer**

- I have always had positive evaluations of my courses.
- I find it important to challenge and engage students and focus on teaching quality.
- Presently and in the next years I will focus on development of online courses, and how to blend in online elements into traditional theoretical and practical courses.